Assertio Holdings Inc SEC Filings

Assertio Holdings (ASRT): A company director reported an open‑market sale of 8,959 shares of common stock on 11/10/2025 at a $0.7597 weighted average price. The sale was made under a Rule 10b5‑1 trading plan adopted on November 22, 2024. Following the transaction, the director reported 98,541 shares beneficially owned, held directly. The trade included multiple executions between $0.7544 and $0.7668 per share.

Assertio Holdings (ASRT) reported stronger Q3 2025 results, with total revenue of $49.5 million, up from $29.2 million a year ago, and net income of $11.4 million versus a prior-year loss. Diluted EPS was $0.11. Growth was led by ROLVEDON product sales of $38.6 million in the quarter.

Management noted that Q3 included large distributor purchases of ROLVEDON to support integration into Assertio Specialty, accompanied by higher discounts and extended payment terms. The company anticipates no material net product sales of ROLVEDON in Q4 2025 and Q1 2026, with regular sales of newly labeled product expected to begin in Q2 2026.

For the nine months, revenue was $105.2 million and net loss was $18.4 million, reflecting an $8.2 million loss on the Assertio Therapeutics divestiture and portfolio actions. Cash and cash equivalents were $38.5 million and short-term investments were $54.9 million as of September 30, 2025; accounts receivable rose to $141.3 million and accrued rebates/returns/discounts to $130.5 million tied to Q3 sales terms. The company recorded a $1.7 million SPRIX intangible impairment and revised SPRIX’s remaining life to one year. Long-term debt consisted of $40.0 million principal of 6.5% convertible notes due 2027. Shares outstanding were 96,252,087 as of November 6, 2025.

Assertio Holdings (ASRT) reported two updates. The company furnished a press release announcing financial results for the three and nine months ended September 30, 2025, and named Paul Schwichtenberg as President and Chief Operating Officer, effective November 3, 2025. Schwichtenberg previously served as Chief Transformation Officer. The press release was filed as Exhibit 99.1 and the Item 2.02 information was furnished, not filed.

Assertio Holdings announced a leadership change. Effective October 27, 2025, Brendan O’Grady separated from service as Chief Executive Officer under an “Other Involuntary Termination” per his Management Continuity Agreement. The Board appointed director Mark Reisenauer as Chief Executive Officer, and he will continue to serve on the Board.

Under his offer letter, Reisenauer will receive a base salary of $800,000 per year and an annual target cash bonus opportunity of 85% of base salary, though he will not be eligible for a cash bonus for the remainder of 2025. He will be granted an option to purchase 1,000,000 shares and 500,000 RSUs, each vesting one-third annually over three years under the company’s 2014 Omnibus Incentive Plan. His Management Continuity Agreement provides change-in-control protections, including cash severance equal to two times base salary and two times target bonus, up to 24 months of paid health benefits, accelerated vesting of unvested equity, and outplacement services; outside a change-in-control period, severance includes 18 months of salary continuation, paid health benefits for up to 18 months, earned but unpaid prior-year bonus, and limited outplacement.

Assertio Holdings (ASRT) reported lower revenue and wider losses for the quarter and first half of 2025 while taking strategic steps to simplify the business. Total revenues were $29.2 million for the three months and $55.7 million for the six months ended June 30, 2025, down from $31.1 million and $63.6 million a year earlier, respectively, driven by lower INDOCIN sales despite higher ROLVEDON sales of $16.1 million in the quarter. Cost pressures included higher amortization of intangibles of $9.2 million in the quarter.

The company recorded a net loss of $16.4 million ($0.17 per share) for the quarter and $29.9 million ($0.31 per share) for the six months, which includes an $8.2 million loss on the divestiture of Assertio Therapeutics. Total assets declined to $273.8 million and shareholders' equity fell to $93.3 million. Cash and cash equivalents were $47.1 million with short-term investments of $51.1 million.

Material operational items: the Therapeutics divestiture removed Assertio from opioid-related litigation exposure but produced an $8.2 million loss; the company ceased commercialization of Otrexup (incurring $3.8 million of related costs); management recorded a $16.0 million accrual related to the Luo settlement with corresponding insurance recoverable that was later settled and reduced to zero. The company maintains $39.0 million of 6.5% convertible notes due 2027 and a full valuation allowance on deferred tax assets.